<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This double-blind study investigated the efficacy and safety of rapid-acting intramuscular <z:chebi fb="0" ids="7735">olanzapine</z:chebi> in treating <z:hpo ids='HP_0000713'>agitation</z:hpo> associated with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> and/or vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>At 2 h, <z:chebi fb="0" ids="7735">olanzapine</z:chebi> (5.0 mg, 2.5 mg) and lorazepam (1.0 mg) showed significant improvement over placebo on the PANSS Excited Component (PANSS-EC) and <z:hpo ids='HP_0000713'>Agitation</z:hpo>-Calmness Evaluation Scale (<z:chebi fb="10" ids="39061">ACES</z:chebi>), and both 5.0 mg <z:chebi fb="0" ids="7735">olanzapine</z:chebi> and lorazepam showed superiority to placebo on the Cohen-Mansfield <z:hpo ids='HP_0000713'>Agitation</z:hpo> Inventory </plain></SENT>
<SENT sid="2" pm="."><plain>At 24 h, both <z:chebi fb="0" ids="7735">olanzapine</z:chebi> groups maintained superiority over placebo on the PANSS-EC; lorazepam did not </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="7735">Olanzapine</z:chebi> (5.0 mg) and lorazepam improved <z:chebi fb="10" ids="39061">ACES</z:chebi> scores more than placebo </plain></SENT>
<SENT sid="4" pm="."><plain>Simpson-Angus and Mini-Mental State Examination scores did not change significantly from baseline </plain></SENT>
<SENT sid="5" pm="."><plain>Sedation (<z:chebi fb="10" ids="39061">ACES</z:chebi> &gt; or =8), adverse events, and laboratory analytes were not significantly different from placebo for any treatment </plain></SENT>
<SENT sid="6" pm="."><plain>No significant differences among treatment groups were seen in <z:hpo ids='HP_0002071'>extrapyramidal symptoms</z:hpo> or in corrected QT interval at either 2 h or 24 h, and no significant differences among treatment groups were seen in vital signs, including orthostasis </plain></SENT>
<SENT sid="7" pm="."><plain>Intramuscular injection of <z:chebi fb="0" ids="7735">olanzapine</z:chebi> may therefore provide substantial benefit in rapidly treating inpatients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0000726'>dementia</z:hpo>-related <z:hpo ids='HP_0000713'>agitation</z:hpo> </plain></SENT>
</text></document>